Quality control and drug development used to remove the latest technical and regulatory barriers. After a successful outcome of the project, the first clinical studies can be set up within one year to demonstrate the safety and functioning of the product in a relevant operational environment and thus take the next step towards the treatment of patients with PC. Also, the results regarding our injectable hydrogel may be applicable in the treatment of other cancers that may benefit from targeted local therapy with fewer side effects. This means that patients can be treated faster and more specifically and where their quality of life is central.